CWM
IKT icon

CCG Wealth Management’s Inhibikase Therapeutics IKT Stock Holding History

CCG Wealth Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,118
Closed -$40.5K – 154
2026
Q1 		$40.5K Buy
+24,118
New +$42.8K 0.01% 132
2023
Q2 		– Sell
-5,000
Closed -$19.7K – 67
2023
Q1 		$19.7K Hold
5,000
– – 0.01% 62
2022
Q4 		$15K Buy
5,000
+1,667
+50% +$6.61K 0.01% 101
2022
Q3 		$18K Buy
+3,333
New +$17.5K 0.01% 95

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCG Wealth Management's IKT Position: Q2 2026 in Review

CCG Wealth Management sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 24,118 shares — an estimated $40.5K sold.

CCG Wealth Management first reported a position in IKT in Q3 2022 and held it in 4 quarters. The position peaked at $40.5K in Q1 2026. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • CCG Wealth Management reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • CCG Wealth Management sold 24,118 Inhibikase Therapeutics shares in Q2 2026, an estimated $40.5K.
  • CCG Wealth Management first reported a position in Inhibikase Therapeutics in Q3 2022 and held it in 4 quarters.
  • CCG Wealth Management's Inhibikase Therapeutics position peaked at $40.5K in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on CCG Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.